Genmab — April 2017
-
Og i bund og grund har Jan jo også talt delvist varmt om mindst 7 indikationer i blodcancer udenfor MM, men jeg kunne godt tænke mig at Jan kom på banen og var lidt mere konkret - som Bulder også skriver. Håber de spørger ind til dette hos Kempen midt i april
-
Omsætning på 500 mio efter en time!
-
I øvrigt har Janssen tydeligvis også overvejet at kombinere CHOP eller R-CHOP i DLBCL med daratumumab: http://www.freepatentsonline.com/y2015/0246123.html
-
Alm. Brand: Bund i 1.200
-
-
http://www.genmab.com/careers/current-vacancies/vacancy-list-details?id=971bc180-f716-61f4-a1a3-ff0000de49ab&lid=971bc180-f716-61f4-a1a3-ff0000de49ab
They are still looking for a Patent Attorney if you are interested gentogen
-
-
1.240 var et stærkt gulv. Vil tro at flere i A/B gruppen har timet efter det niveau.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind